Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Assessment of disease activity in muscular dystrophies by noninvasive imaging
Katie K. Maguire, … , Sedona Speedy, Thomas A. Rando
Katie K. Maguire, … , Sedona Speedy, Thomas A. Rando
Published April 24, 2013
Citation Information: J Clin Invest. 2013;123(5):2298-2305. https://doi.org/10.1172/JCI68458.
View: Text | PDF
Technical Advance

Assessment of disease activity in muscular dystrophies by noninvasive imaging

  • Text
  • PDF
Abstract

Muscular dystrophies are a class of disorders that cause progressive muscle wasting. A major hurdle for discovering treatments for the muscular dystrophies is a lack of reliable assays to monitor disease progression in animal models. We have developed a novel mouse model to assess disease activity noninvasively in mice with muscular dystrophies. These mice express an inducible luciferase reporter gene in muscle stem cells. In dystrophic mice, muscle stem cells activate and proliferate in response to muscle degeneration, resulting in an increase in the level of luciferase expression, which can be monitored by noninvasive, bioluminescence imaging. We applied this noninvasive imaging to assess disease activity in a mouse model of the human disease limb girdle muscular dystrophy 2B (LGMD2B), caused by a mutation in the dysferlin gene. We monitored the natural history and disease progression in these dysferlin-deficient mice up to 18 months of age and were able to detect disease activity prior to the appearance of any overt disease manifestation by histopathological analyses. Disease activity was reflected by changes in luciferase activity over time, and disease burden was reflected by cumulative luciferase activity, which paralleled disease progression as determined by histopathological analysis. The ability to monitor disease activity noninvasively in mouse models of muscular dystrophy will be invaluable for the assessment of disease progression and the effectiveness of therapeutic interventions.

Authors

Katie K. Maguire, Leland Lim, Sedona Speedy, Thomas A. Rando

×

Figure 5

Histological analyses of muscles of Dysf–/–/Pax7CreER/LuSEAP mice over time.

Options: View larger image (or click on image) Download as PowerPoint
Histological analyses of muscles of Dysf–/–/Pax7CreER/LuSEAP mice over t...
(A) Cryosections of quadriceps muscles of 3-, 6-, 9-, and 12-month-old mice were stained with H&E to assess for histopathologic evidence of disease progression. (B) Quantitative analysis of the percentages of centrally nucleated myofibers in quadriceps of Dysf–/–/Pax7CreER/LuSEAP mice as a function of age. *P < 0.05, **P < 0.005; n = 3; value at each time point compared with that at 3 months of age. (C) Analysis of serial sections from muscles of mice as in panel A were stained with an antibody against eMyHc to assay for regenerating myofibers. (D) Quantitative analysis of the percentages of eMyHc-positive fibers in the quadriceps muscles of Dysf–/–/Pax7CreER/LuSEAP mice as a function of age. **P < 0.05, ***P < 0.001; n = 3; value at each time point compared with that at 3 months of age. Scale bars: 50 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts